Newbridge Financial Services Group’s Rhythm Pharmaceuticals RYTM Stock Holding History

Newbridge Financial Services Group’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-65	Closed	-$1.49K	–	1302
2023 Q3	$1.49K	Hold	65	–	–	﹤0.01%	1116
2023 Q2	$1.07K	Hold	65	–	–	﹤0.01%	1209
2023 Q1	$1.16K	Hold	65	–	–	﹤0.01%	1257
2022 Q4	$1.89K	Hold	65	–	–	﹤0.01%	1223
2022 Q3	$2K	Hold	65	–	–	﹤0.01%	1230
2022 Q2	$0	Hold	65	–	–	﹤0.01%	1498
2022 Q1	$1K	Hold	65	–	–	﹤0.01%	1398
2021 Q4	$1K	Hold	65	–	–	﹤0.01%	1355
2021 Q3	$1K	Hold	65	–	–	﹤0.01%	1305
2021 Q2	$1K	Hold	65	–	–	﹤0.01%	1387
2021 Q1	$1K	Buy	+65	New	+$1.89K	﹤0.01%	1318

Other funds holding RYTM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Newbridge Financial Services Group's RYTM Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2023, closing a stake of 65 shares — an estimated $1.49K sold.

Newbridge Financial Services Group first reported a position in RYTM in Q1 2021 and held it in 11 quarters. The position peaked at $2K in Q3 2022. 168 funds tracked by Wall St. Rank hold RYTM as of Q4 2023.

Newbridge Financial Services Group reported no remaining Rhythm Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Newbridge Financial Services Group sold 65 Rhythm Pharmaceuticals shares in Q4 2023, an estimated $1.49K.
Newbridge Financial Services Group first reported a position in Rhythm Pharmaceuticals in Q1 2021 and held it in 11 quarters.
Newbridge Financial Services Group's Rhythm Pharmaceuticals position peaked at $2K in Q3 2022.
168 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.